Cargando…

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)

SIMPLE SUMMARY: The characterization of clinical outcomes and prognostic factors in COVID-19-infected cancer patients is important for health care authorities, policy makers and oncologists. We collected extensive data on COVID-19-infected cancer patients from 1 March 2020 over a one-year period. Am...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joerger, Markus, Metaxas, Yannis, Zaman, Khalil, Michielin, Olivier, Mach, Nicolas, Bettini, Adrienne, Schmitt, Andreas M., Cantoni, Nathan, Caspar, Clemens B., Stettler, Sonja, Malval, Roma, Pless, Miklos, Britschgi, Christian, Renner, Christoph, Koeberle, Dieter, Schulz, Jessica D., Kopp, Christoph, Hayoz, Stefanie, Stathis, Anastasios, von Moos, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104745/ https://www.ncbi.nlm.nih.gov/pubmed/35565320 http://dx.doi.org/10.3390/cancers14092191

Ejemplares similares

1570P Outcome and prognostic factors of COVID-19 infection in cancer patients: Final results of SAKK 80/20
por: Joerger, M., et al.
Publicado: (2021)

LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
por: Joerger, M., et al.
Publicado: (2020)

Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK)
por: Hayoz, Stefanie, et al.
Publicado: (2023)

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
por: König, D., et al.
Publicado: (2022)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
por: Mark, M., et al.
Publicado: (2022)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2019)

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC
por: Blum, David, et al.
Publicado: (2012)

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
por: Mark, Michael, et al.
Publicado: (2019)

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
por: Joerger, Markus, et al.
Publicado: (2019)

SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
por: Vetter, Marcus, et al.
Publicado: (2022)

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study †
por: Genta, Sofia, et al.
Publicado: (2022)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
por: Pestalozzi, Bernhard C., et al.
Publicado: (2017)

Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy
por: Panje, Cédric M., et al.
Publicado: (2019)

Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94)
por: Ghadjar, Pirus, et al.
Publicado: (2015)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13)
por: Novak, Urban, et al.
Publicado: (2023)

Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)
por: Ribi, Karin, et al.
Publicado: (2021)

Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
por: Varga, Zsuzsanna, et al.
Publicado: (2019)

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
por: König, D., et al.
Publicado: (2023)

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19)
por: Petrausch, Ulf, et al.
Publicado: (2023)

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
por: Juskevicius, Darius, et al.
Publicado: (2017)

High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
por: Fehr, Martin, et al.
Publicado: (2020)

Automated analysis of calcium spiking profiles with CaSA software: two case studies from root-microbe symbioses
por: Russo, Giulia, et al.
Publicado: (2013)

Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis
por: Stürner, Klarissa Hanja, et al.
Publicado: (2020)

Nottetempo, casa per casa : romanzo /
por: Consolo, Vincenzo, 1933-2012

De noche, casa por casa
por: Consolo, Vincenzo, 1933-2012

Casas /
por: Sejima, Kazuyo, 1956-
Publicado: (2007)

Casas /
por: Mostaedi, Arian
Publicado: (2004)

Spas en casa = Spas em casa /
Publicado: (2005)

Casas de vidrio = casas de vidro
Publicado: (2005)

Standardization for Ki-67 Assessment in Moderately Differentiated Breast Cancer. A Retrospective Analysis of the SAKK 28/12 Study
por: Varga, Zsuzsanna, et al.
Publicado: (2015)

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
por: Rochlitz, Christoph, et al.
Publicado: (2016)

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study
por: Tzankov, Alexandar, et al.
Publicado: (2015)

Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study
por: Joerger, Markus, et al.
Publicado: (2023)

Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)
por: Weber, Walter P., et al.
Publicado: (2023)

Casas unifamiliares : la casa actual
por: Chueca, Pilar
Publicado: (2008)

De casa a casa : correspondencia entre Manuel Toussaint y Alfonso Reyes /
por: Toussaint, Manuel, 1890-1955
Publicado: (1990)

External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26
por: Herrmann, Evelyn, et al.
Publicado: (2017)

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)
por: Hitz, F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_adttcc7ir5rnjbcgb8cpdt3ch1